NCCN Guidelines for Patients® | Esophageal Cancer - page 73

73
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 6: Adenocarcinomas
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Other regimens
• Paclitaxel and cisplatin
• Docetaxel and cisplatin
• Irinotecan and cisplatin
• Paclitaxel and fluoropyrimidine (5-FU or capecitabine)
• Docetaxel and fluoropyrimidine (5-FU or capecitabine)
Other options include surgery, chemotherapy, or supportive care. If the cancer
returns as M0 disease after chemoradiation with no prior esophagectomy, your
doctor will assess if you can have surgery and if the tumor can be removed. If
not, supportive care should be given. Supportive care is also recommended for
distant metastases (M1 disease).
Next steps:
When you are finished with cancer treatment, read Part 6.3 for
follow-up care. If you will receive chemotherapy or supportive care, read
Part 6.5 next.
Definitions:
concurrent
chemoradiation:
Chemotherapy and
radiation therapy given at
the same time
Supportive care:
Treatment for symptoms
that are caused by cancer
or by cancer treatment
!
Read pages 28–38
for information on
cancer treatments.
1...,63,64,65,66,67,68,69,70,71,72 74,75,76,77,78,79,80,81,82,83,...100
Powered by FlippingBook